{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:57:03Z","timestamp":1760101023042,"version":"3.40.5"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.eururo.2017.11.021","type":"journal-article","created":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T00:00:19Z","timestamp":1512172819000},"page":"749-750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Current State of Predicting Response on Bacillus Calmette-Gu\u00e9rin Treatment for Nonmuscle Invasive Bladder Cancer is Not Yet Useful for Patients but Attributes to Understanding Its Mechanisms of Action"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6079-5613","authenticated-orcid":false,"given":"Jorg R.","family":"Oddens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo M.","family":"de Reijke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2017.11.021_bib0055","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.11.021_bib0060","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumours","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.11.021_bib0065","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine Panel for Response to Intravesical Therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to bacillus Calmette-Guerin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.11.021_bib0370","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","article-title":"Predicting response to intravesical bacillus Calmette-Gu\u00e9rin immunotherapy: are we there yet?. A systematic review","volume":"73","author":"Kamat","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.11.021_bib0075","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","article-title":"Markers predicting response to bacillus Calmette-Gu\u00e9rin immunotherapy in high-risk bladder cancer patients: a systematic review","volume":"61","author":"Zuiverloon","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.11.021_bib0080","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.juro.2011.10.144","article-title":"Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guerin therapy for bladder cancer: results of a prospective trial","volume":"187","author":"Kamat","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.11.021_bib0085","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Gu\u00e9rin","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.11.021_bib0090","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin c versus bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.11.021_bib0095","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.eururo.2005.05.004","article-title":"BCG dose reduction by decreasing the instillation frequency: effects on local Th1\/Th2 cytokine responses in a mouse model","volume":"48","author":"de Boer","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.11.021_bib0100","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283817310060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283817310060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T10:19:51Z","timestamp":1529662791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283817310060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0302283817310060"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2017.11.021","relation":{},"ISSN":["0302-2838"],"issn-type":[{"type":"print","value":"0302-2838"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Current State of Predicting Response on Bacillus Calmette-Gu\u00e9rin Treatment for Nonmuscle Invasive Bladder Cancer is Not Yet Useful for Patients but Attributes to Understanding Its Mechanisms of Action","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2017.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2017.10.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}